Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-Cell responses to the tumor-specific antigen NY-ESO-1

被引:54
|
作者
Le Gal, FA
Ayyoub, M
Dutoit, V
Widmer, V
Jäger, E
Cerottini, JC
Dietrich, PY
Valmori, D
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Ludwig Inst,Clin Trial Ctr,Div Med Oncol, New York, NY 10032 USA
[2] Univ Hosp Geneva, Div Oncol, Lab Tumor Immunol, Geneva, Switzerland
[3] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
T-cell receptor; repertoire; tumor immunity; vaccination;
D O I
10.1097/01.cji.0000161398.34701.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epilope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines. but they are heterogeneous in terms of functional avidity and tumor reactivity, The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may rail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 11 条
  • [11] Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
    Bauer, Christian
    Sterzik, Alexander
    Bauernfeind, Franz
    Duewell, Peter
    Conrad, Claudius
    Kiefl, Rosemarie
    Endres, Stefan
    Eigler, Andreas
    Schnurr, Max
    Dauer, Marc
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (04) : 321 - 333